SE453514B - Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning - Google Patents
Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypningInfo
- Publication number
- SE453514B SE453514B SE8203041A SE8203041A SE453514B SE 453514 B SE453514 B SE 453514B SE 8203041 A SE8203041 A SE 8203041A SE 8203041 A SE8203041 A SE 8203041A SE 453514 B SE453514 B SE 453514B
- Authority
- SE
- Sweden
- Prior art keywords
- dtk
- isoenzyme
- concentration
- substrate
- serum
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 25
- 239000007788 liquid Substances 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 38
- 239000000758 substrate Substances 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 108010044467 Isoenzymes Proteins 0.000 claims abstract description 14
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 11
- 239000010452 phosphate Substances 0.000 claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 claims abstract description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 10
- 239000007853 buffer solution Substances 0.000 claims abstract description 9
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- 230000001404 mediated effect Effects 0.000 claims abstract description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 3
- 210000001124 body fluid Anatomy 0.000 claims abstract description 3
- 239000010839 body fluid Substances 0.000 claims abstract description 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000009385 viral infection Effects 0.000 abstract description 7
- 238000012544 monitoring process Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000005259 measurement Methods 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 47
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 206010027476 Metastases Diseases 0.000 description 16
- 239000012530 fluid Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 208000017604 Hodgkin disease Diseases 0.000 description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 206010000830 Acute leukaemia Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000007306 turnover Effects 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003622 anti-hsv Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000012928 buffer substance Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001589 lymphoproliferative effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BOFUZZAQNVYZFF-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-methylmorpholine Chemical compound CC1NCCOC1C1=CC=CC(Cl)=C1 BOFUZZAQNVYZFF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000004068 Morbillivirus Infections Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- -1 thymidine anion Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8203041A SE453514B (sv) | 1982-05-14 | 1982-05-14 | Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning |
| AU15540/83A AU551176B2 (en) | 1982-05-14 | 1983-05-10 | A method for determination of deoxythymidine kinase (dtk) isoenzyme activity and use thereof for the diagnosis of diseases |
| US06/576,375 US4637977A (en) | 1982-05-14 | 1983-05-10 | Method of determining dTk isoenzyme activity and the use thereof |
| AT83850122T ATE33504T1 (de) | 1982-05-14 | 1983-05-10 | Verfahren zur feststellung der dtk isoenzymaktivit|t und anwendung des verfahrens. |
| JP58501735A JPS59500796A (ja) | 1982-05-14 | 1983-05-10 | ｄＴｋアイソザイム活性の測定法とその利用 |
| DE8383850122T DE3376272D1 (en) | 1982-05-14 | 1983-05-10 | A method of determining dtk isoenzyme activity and the use thereof |
| PCT/SE1983/000190 WO1983004054A1 (en) | 1982-05-14 | 1983-05-10 | A method for determination of deoxythymidine kinase (dtk) isoenzyme activity and use thereof for the diagnosis of diseases |
| EP83850122A EP0094923B1 (de) | 1982-05-14 | 1983-05-10 | Verfahren zur Feststellung der dTk Isoenzym-Aktivität und Anwendung des Verfahrens |
| ES522376A ES522376A0 (es) | 1982-05-14 | 1983-05-13 | Procedimiento para determinar el nivel de isoenzima dtk en una muestra de fluido corporal o celular humana o animal. |
| CA000428172A CA1199858A (en) | 1982-05-14 | 1983-05-13 | Method of determining dtk isoenzyme activity and the use thereof |
| NO840117A NO165599C (no) | 1982-05-14 | 1984-01-13 | En metode for bestemmelse av dtk isoenzym-aktivitet og anvendelse av denne for in vitro diagnostisering av sykdommer |
| DK016384A DK167692B1 (da) | 1982-05-14 | 1984-01-13 | Fremgangsmaade til bestemmelse af deoxythymidinkinase (dtk)isoenzymniveauer samt anvendelse af fremgangsmaaden |
| FI840134A FI77895C (fi) | 1982-05-14 | 1984-01-13 | Foerfarande foer bestaemning av deoxithymidinkinas-isoentsymaktivitet och dess anvaendning foer diagnosis av sjukdomar. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8203041A SE453514B (sv) | 1982-05-14 | 1982-05-14 | Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8203041L SE8203041L (sv) | 1983-11-15 |
| SE453514B true SE453514B (sv) | 1988-02-08 |
Family
ID=20346817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8203041A SE453514B (sv) | 1982-05-14 | 1982-05-14 | Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4637977A (de) |
| EP (1) | EP0094923B1 (de) |
| JP (1) | JPS59500796A (de) |
| AT (1) | ATE33504T1 (de) |
| AU (1) | AU551176B2 (de) |
| CA (1) | CA1199858A (de) |
| DE (1) | DE3376272D1 (de) |
| DK (1) | DK167692B1 (de) |
| ES (1) | ES522376A0 (de) |
| FI (1) | FI77895C (de) |
| SE (1) | SE453514B (de) |
| WO (1) | WO1983004054A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816410A (en) * | 1986-10-29 | 1989-03-28 | Coulter Corporation | Control slide for immunoassay kit and method of making same |
| ATE352039T1 (de) * | 2002-07-27 | 2007-02-15 | Diasorin Ab | Verfahren zur bestimmung der aktivität von thymidinkinase-1 und dessen verwendung |
| CA2598726C (en) * | 2005-02-25 | 2014-02-18 | Ronnerbol Holding Ab | A method and kit for determination of thymidine kinase activity and use thereof |
| US20220221456A1 (en) * | 2019-05-06 | 2022-07-14 | Arocell Ab | Respiratory infection detection and classification |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4302535A (en) * | 1979-09-27 | 1981-11-24 | Massachusetts Institute Of Technology | Assay for mutagenesis in heterozygous diploid human lymphoblasts |
| US4317877A (en) * | 1980-06-05 | 1982-03-02 | Sloan Kettering Institute | Process for detecting the presence of malignant and pre-malignant cells in humans |
| IE64317B1 (en) * | 1989-10-26 | 1995-07-26 | Walbro Corp | Fuel metering method and apparatus |
-
1982
- 1982-05-14 SE SE8203041A patent/SE453514B/sv not_active IP Right Cessation
-
1983
- 1983-05-10 JP JP58501735A patent/JPS59500796A/ja active Granted
- 1983-05-10 AT AT83850122T patent/ATE33504T1/de not_active IP Right Cessation
- 1983-05-10 EP EP83850122A patent/EP0094923B1/de not_active Expired
- 1983-05-10 AU AU15540/83A patent/AU551176B2/en not_active Ceased
- 1983-05-10 US US06/576,375 patent/US4637977A/en not_active Expired - Lifetime
- 1983-05-10 DE DE8383850122T patent/DE3376272D1/de not_active Expired
- 1983-05-10 WO PCT/SE1983/000190 patent/WO1983004054A1/en not_active Ceased
- 1983-05-13 CA CA000428172A patent/CA1199858A/en not_active Expired
- 1983-05-13 ES ES522376A patent/ES522376A0/es active Granted
-
1984
- 1984-01-13 FI FI840134A patent/FI77895C/fi not_active IP Right Cessation
- 1984-01-13 DK DK016384A patent/DK167692B1/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK16384A (da) | 1984-01-13 |
| CA1199858A (en) | 1986-01-28 |
| DE3376272D1 (en) | 1988-05-19 |
| FI77895C (fi) | 1989-05-10 |
| EP0094923B1 (de) | 1988-04-13 |
| FI77895B (fi) | 1989-01-31 |
| WO1983004054A1 (en) | 1983-11-24 |
| EP0094923A3 (en) | 1985-07-24 |
| AU551176B2 (en) | 1986-04-17 |
| US4637977A (en) | 1987-01-20 |
| ATE33504T1 (de) | 1988-04-15 |
| EP0094923A2 (de) | 1983-11-23 |
| ES8402876A1 (es) | 1984-03-01 |
| SE8203041L (sv) | 1983-11-15 |
| JPH051000B2 (de) | 1993-01-07 |
| FI840134A0 (fi) | 1984-01-13 |
| FI840134A7 (fi) | 1984-01-13 |
| DK167692B1 (da) | 1993-12-06 |
| JPS59500796A (ja) | 1984-05-10 |
| ES522376A0 (es) | 1984-03-01 |
| DK16384D0 (da) | 1984-01-13 |
| AU1554083A (en) | 1983-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230272476A1 (en) | Nano46 genes and methods to predict breast cancer outcome | |
| EP1996940B1 (de) | Nachweis von krebs anhand von erhöhten bcl-2-konzentrationen | |
| Maloney et al. | Distribution of suboptimally induced β-D-Galactosidase in Escherichia coli: the enzyme content of individual cells | |
| Wu et al. | Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays | |
| US20170370933A1 (en) | Methods and compositions for immunomodulation | |
| Viscidi et al. | Molecular diagnosis of infectious diseases by nucleic acid hybridization | |
| Goldstein et al. | Cystathionine synthase activity in human lymphocytes: induction by phytohemagglutinin | |
| Bartram et al. | Monitoring MRD in ALL: methodologies, technical aspects and optimal time points for measurement | |
| Tiwari et al. | Application of enzyme amplified mycobacterial DNA detection in the diagnosis of pulmonary & extra-pulmonary tuberculosis | |
| CN105648058A (zh) | 一种评估肝癌预后的试剂盒 | |
| Zhong et al. | Gross elevation of TT virus genome load in the peripheral blood mononuclear cells of cancer patients | |
| Sprouse et al. | T-Cell Clonality Determination Using Polymerase ChainReaction (PCR) Amplification of the T-Cell Receptorgamma-Chain Gene and Capillary Electrophoresis ofFluorescently Labeled PCR Products | |
| US20160115551A1 (en) | Methods to predict risk of recurrence in node-positive early breast cancer | |
| Fisher et al. | Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance | |
| de la Iglesia-San Sebastián et al. | Digital PCR improves sensitivity and quantification in monitoring CAR-T cells in B cell lymphoma patients | |
| CN104109716A (zh) | 一种人类hla-b27基因分型试剂盒 | |
| Fox et al. | Sensitivity of leukemic human null lymphocytes to deoxynucleosides | |
| CN102634572A (zh) | 一种荧光定量RT-PCR检测融合基因E2A-PBX1 mRNA表达的试剂盒 | |
| US20160046997A1 (en) | Biomarkers for cervical cancer | |
| Nakamichi et al. | Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma | |
| SE453514B (sv) | Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning | |
| CN104195255A (zh) | 一种检测融合基因AML1-ETO mRNA表达的试剂盒及其检测方法 | |
| Yu et al. | Thymidylate synthase predicts for clinical outcome in invasive breast cancer | |
| KR20090025898A (ko) | 폐암 환자의 폐암 재발 위험을 예측하기 위한 마커, 키트,마이크로어레이 및 방법 | |
| Kahan et al. | Increased activity in serum of an alkaline phosphatase isoenzyme in cancer: analytical method and preliminary clinical studies. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8203041-2 Effective date: 19910123 Format of ref document f/p: F |